· Investment Strategies · 3 sources
Thyme Care’s $125M Series E: Oncology Navigation Clears $2B With Payer Capital
Morgan Health led Thyme Care’s $125M+ Series E above a $2B valuation — Humana, CVS Health Ventures, AlleyCorp, and a16z Bio + Health joined as the company spins up Thyme Companies for biosimilars and trial access.
Editorial team
Morgan Health led Thyme Care’s $125 million+ Series E on September 2, 2026, taking the Nashville oncology company above a $2 billion valuation — roughly 2× its Series D less than a year earlier (company PR; CNBC).
Spine: payer strategics (Humana, CVS Health Ventures) and long-time VC owners (AlleyCorp, a16z Bio + Health, Frist Cressey) are financing a platform parent — Thyme Companies — not just more navigation seats.
Key facts
- Company
- Thyme Care (Nashville)
- Round
- $125M+ Series E
- Valuation
- >$2B (company / CNBC)
- Lead
- Morgan Health (JPMorgan)
- Strategics
- Humana; CVS Health Ventures
- Directory VCs
- AlleyCorp; a16z; Frist Cressey
- Also
- HealthQuest; Foresite; Concord Health Partners; Town Hall Ventures
- Structure move
- New parent Thyme Companies for biosimilars + trial accrual businesses
Who uses the product — and for what job
Users: health plans and employers managing oncology spend; community oncologists in value-based arrangements; patients navigating treatment logistics.
Job: fill the gaps that clinics and PBMs leave open — symptom triage, social support, care coordination — so outcomes improve while total cost of cancer care falls. CNBC frames the product as a virtual navigation platform; the company positions Thyme Box as the operating system for that work.
This is payer-aligned oncology operations, not a consumer wellness app.
Why now
- Series D (~$97M, Fierce) was less than a year ago — the double to >$2B signals commercial proof, not a seed-story rebrand.
- Drug affordability, biosimilar uptake, and trial enrollment remain structural bottlenecks; Thyme Companies is the explicit bet that navigation data can spawn adjacent businesses.
- Strategics Humana and CVS sitting next to Morgan Health is the distribution thesis in capital form.
Why these funds — portfolio fit
| Investor | Likely fit |
|---|---|
| Morgan Health | JPMorgan’s healthcare investing arm underwriting payer-grade cost/quality evidence |
| Humana / CVS Health Ventures | Buyers who can embed navigation into plan and retail-health channels |
| AlleyCorp | Long-cycle healthcare operator capital; returning owner from earlier rounds |
| a16z Bio + Health | Continuity from Series B thesis — oncology VBC as a category, not a feature |
| Frist Cressey | Healthcare services / provider-adjacent growth |
Likely founder rationale: raise from the payers who write the checks for cancer care, then keep multi-stage VCs who already know the unit economics — not a cold growth-equity auction.
Morgan Health, Humana, CVS Health Ventures, Foresite, Town Hall, HealthQuest, and Concord are covered editorially without inventing /fund/ pages.
Competitive map
| Layer | Players | Difference |
|---|---|---|
| Specialty VBC navigation | Thyme Care | Oncology-only; payer risk alignment |
| Primary-care VBC | Oak Street / agilon-style models | Different specialty economics |
| Incumbent nav / PBM services | Health-system and PBM teams | Often less tech-native; harder to productize across markets |
What is not proven
- Exact post-money figure above “more than $2B” is not broken out.
- Revenue, membership counts, and medical-cost savings vs control are not disclosed in the Series E release.
- Thyme Companies’ first business is expected later in 2026 — not live.
Practical takeaway
- Founders (health): A Series E with Morgan Health + Humana + CVS is a distribution financing, not a vanity round — show payer-ready outcomes.
- Investors: Underwrite whether Thyme Companies dilutes focus or compounds a data moat.
- Operators / journalists: The story is parent-entity expansion into biosimilars and trials, not another “AI care chat” headline.
Sources
Follow Venture Capital Tracker in Google
Add VCT as a preferred source to make our venture-capital coverage easier to find in Google Search.
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.
